Kancera announces start of Phase 1 Multiple Ascending Dose Trial of KAND567
Kancera today launches the second part of the ongoing clinical Phase I study of KAND567. During this part of the study, KAND567 is administered to groups of healthy subjects in increasing doses, twice a day for seven days. The...
Read More